BrickBio’s antibody-drug conjugate BRKB-28 showed preclinical effectiveness in eradicating breast cancer cells while leaving healthy cells unharmed, the company announced. BRKB-28 combines an antibody against a cancer protein with a toxic payload, using a linker molecule that connects the two. Once bound to its target, BRKB-28 releases its toxic compound into cancer cells, triggering their death. Designed with BrickBio’s bioconjugation platform, BRKB-28, which is also being developed for gastric cancer, showed a better performance than…
You must be logged in to read/download the full post.
The post Antibody-drug Combo Shows Early Promise in Targeting Cancers, Company Says appeared first on BioNewsFeeds.